Optimal Interval for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Stable Infliximab Maintenance Treatment

被引：0
|
作者：
Hong, S. N. [1 ]
Yujin, L. [1 ]
Boram, P. [2 ]
Soon, J. Ok [3 ]
Ho, K. Young [1 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Dept Med, Samsung Med Ctr, Seoul, South Korea
[2] Samsung Med Ctr, Biomed Stat Ctr, Res Inst Future Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Dept Data Serv Team, Samsung Med Ctr, Seoul, South Korea
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P353
引用
收藏
页码：I745 / I745
页数：1
相关论文
共 50 条
  • [31] Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study
    Paul, Stephane
    Del Tedesco, Emilie
    Marotte, Hubert
    Clavel, Lea
    Phelip, Jean Marc
    Peyrin-Biroulet, Laurent
    Roblin, Xavier
    GASTROENTEROLOGY, 2013, 144 (05) : S92 - S92
  • [32] Therapeutic Drug Monitoring of Adalimumab in Patients With Inflammatory Bowel Disease
    El-Matary, Wael
    CROHNS & COLITIS 360, 2019, 1 (03)
  • [33] Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients on Vedolizumab
    Ansari, Mohammed
    Glassner, Kerri
    Irani, Malcolm
    Perry, Caroline
    Abraham, Bincy P.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S435 - S436
  • [34] Therapeutic drug monitoring in inflammatory bowel disease patients on vedolizumab
    Ansari, Mohammed
    Glassner, Kerri
    Irani, Malcolm
    Saleh, Adam
    Wang, Lin
    Ezeana, Chika
    Wong, Stephen
    Perry, Caroline
    Abraham, Bincy
    JOURNAL OF DIGESTIVE DISEASES, 2024, 25 (02) : 91 - 99
  • [35] Therapeutic drug monitoring in patients with inflammatory bowel disease on ustekinumab
    Saleh, Adam
    Stading, Rachel
    Miroballi, Natalia
    Glassner, Kerri
    Abraham, Bincy P.
    JOURNAL OF DIGESTIVE DISEASES, 2024, 25 (04) : 214 - 221
  • [36] Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring
    Wiken, Thea H.
    Hoivik, Marte L.
    Buer, Lydia
    Warren, David J.
    Bolstad, Nils
    Moum, Bjorn A.
    Anisdahl, Karoline
    Smastuen, Milada C.
    Medhus, Asle W.
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2023, : 863 - 873
  • [37] Infliximab trough levels are decreasing overtime in patients with inflammatory bowel disease on maintenance treatment with infliximab
    Orfanoudaki, E.
    Gazouli, M.
    Foteinogiannopoulou, K.
    Theodouraki, E.
    Legaki, E.
    Koutroubakis, I.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S330 - S331
  • [38] Clinical Value of Proactive Infliximab Drug Monitoring in Patients With Inflammatory Bowel Disease
    Orfanoudaki, Eleni
    Foteinogiannopoulou, Kalliopi
    Theodoraki, Eirini
    Koutroubakis, Ioannis E.
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (06) : E50 - E50
  • [39] PREDICTIVE MODEL FOR CLINICAL OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RECEIVING MAINTENANCE THERAPY WITH INFLIXIMAB
    Wong, Rochelle
    Charilaou, Paris
    Hemperly, Amy
    Qin, Lihui
    Pan, Yushan
    Mahtani, Prerna
    Longman, Randy S.
    Boland, Brigid S.
    Dulai, Parambir S.
    Holmer, Ariela
    Lukin, Dana J.
    Singh, Siddharth
    Valasek, Mark A.
    Sandborn, William J.
    Scherl, Ellen J.
    Casteele, Niels Vande
    Battat, Robert J.
    GASTROENTEROLOGY, 2023, 164 (06) : S1116 - S1116
  • [40] Therapeutic drug monitoring in inflammatory bowel disease
    Kopylov, Uri
    Ben-Horin, Shomron
    Seidman, Ernest
    ANNALS OF GASTROENTEROLOGY, 2014, 27 (04): : 304 - 312
12345